Evaluation of a new durable insulin pen with memory function among people with diabetes and healthcare professionals

Expert Opinion on Drug Delivery

Volumn 9, Issue 4, 2012, Pages 355-366

  Guo, Xiaohui ^a   Sommavilla, Bärbel ^b   Vanterpool, Grace ^c   Qvist, Marianne ^d   Bethien, Matthias ^e   Lilleøre, Søren Kruse ^d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b St Johanns Spital   (Austria)

^c CENTRAL LONDON COMMUNITY HEALTHCARE NHS TRUST   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

^e GfK SirValUse Consulting GmbH   (Germany)

Author keywords

Diabetes; Ease of use; Insulin pen; Memory function

Indexed keywords

CLIKSTAR; HUMAPEN; INSULIN DERIVATIVE; MEMOIR; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINA; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GERMANY; HEALTH CARE PERSONNEL; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEMORY; QUESTIONNAIRE; SCORING SYSTEM; TASK PERFORMANCE; TREATMENT OUTCOME; UNITED KINGDOM;

ARTIFICIAL INTELLIGENCE; CHINA; COMPUTER STORAGE DEVICES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EQUIPMENT DESIGN; GERMANY; HEALTH PERSONNEL; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; PATIENT EDUCATION AS TOPIC; PATIENT PREFERENCE; QUESTIONNAIRES;

EID: 84858801333     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.671808     Document Type: Article

References (44)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
2. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
3. Morrow AS, Haidet P, Skinner J, et al. Integrating diabetes self-management with the health goals of older adults: A qualitative exploration. Patient Educ Couns 2008;72:418-23
4. Lernmark A. Type 1 diabetes. Clin Chem 1999;45:1331-8
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
6. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
7. Brunton S. Insulin delivery systems: Reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med 2008;121:S35-41
8. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-50
9. Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes audit and research in tayside Scotland. medicines monitoring Unit. Lancet 1997;350:1505-10
10. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5
11. Randlov J, Poulsen JU. How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study. J Diabetes Sci Technol 2008;2:229-35
12. Hokkam EN. Assessment of risk factors in diabetic foot ulceration and their impact on the outcome of the disease. Prim Care Diabetes 2009;3:219-24
13. Landman GW, van Hateren KJ, Kleefstra N, et al. The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract 2010;60:172-5
14. Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: An observational study. Lancet 2011;378:140-6
15. Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med 1999;106:57-8; 61-4, 8
16. IMS Health. Estimated number of patients using FlexPen®, based on worldwide sales in number of packs sold, IMS world wide data Q3'08 and Daily Defined Dosage (DDD) for insulin as issued by WHO; 2008
17. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child 1998;79:59-62
18. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila) 2004;43:69-74
19. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999;22:137-40
20. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-48
21. Lombardo F, Salzano G, Messina MF, et al. Compliance and administration methods in management of type 1 diabetes. Acta Biomed 2005;76(Suppl 3):66-9
22. Olsen BS, Lilleore SK, Korsholm CN, et al. Novopen Echo for the delivery of insulin: A comparison of usability, functionality and preference among pediatric subjects, their parents and health care professionals. J Diabetes Sci Tech 2010;4:1468-75
23. Sommavilla B, Jorgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 2008;9:2223-32
24. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498-505
25. Pfutzner A. FlexPen for the delivery of insulin: Accuracy, injection force and patient preference. Expert Rev Med Devices 2009;6:115-23
26. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
27. Asakura T, Seino H, Jensen KH. NovoPen® 4 is easier to teach, more intuitive to use and preferred by patients compared to OptiClik®.. Diabetes 2006;55:A456
28. Donsmark M, Herold L, Kristensen CM. A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4. Diabetes Technol Ther 2009;11:581-5
29. Kristensen CM, Donsmark M. Dose accuracy and durability of the NovoPen 4 insulin delivery device before and after simulation of 5 years of use and under various stress conditions. Clin Ther 2009;31:2819-23
30. Asakura T, Seino H, Jensen KH. Patient acceptance and issues of education of two durable insulin pen devices. Diabetes Technol Ther 2008;10:299-304
31. Israel-Bultman H, Hyllested-Winge J, Kolaczynski M, et al. Comparison of preference for NovoPen((R)) 4 with previous insulin pen treatments after 12 weeks in adult patients with type 1 and type 2 diabetes: A multicenter observational study. Clin Ther 2011;33:346-57
32. World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects. 2008. Available from: Http://wwwriip-influenzaorg/wp-content/uploads/2011/08/Helsinki-2008-ENpdf [Accessed 8 November 2011]
33. Buus P, Lilleore SK, Larsen K. Compatibility testing of two types of pen needles with a range of injection pens for diabetes medication. Curr Med Res Opin 2011;27:589-92
34. Asakura T. Comparison of clinically relevant technical attributes of five insulin injection pens. J Diabetes Sci Technol 2011;5:1203-9
35. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther 2005;7:620-6
36. Chatzimarkakis J. Why patients should be more empowered: A European perspective on lessons learned in the management of diabetes. J Diabetes Sci Technol 2010;4:1570-3
37. LaSalle JR. Empowering patients during insulin initiation: A real-world approach. J Am Osteopath Assoc 2010;110:69-78
38. Rakel RE. Improving patient acceptance and adherence in diabetes management: A focus on insulin therapy. Adv Ther 2009;26:838-46
39. Serrano-Gil M, Jacob S. Engaging and empowering patients to manage their type 2 diabetes, Part I: A knowledge, attitude, and practice gap? Adv Ther 2010;27:321-33
40. Bastian MD, Wolters NE, Bright DR. Insulin pens vs. vials and syringes: Differences in clinical and economic outcomes. Consult Pharm 2011;26:426-9
41. Adolfsson P, Huot C, Veijola R, et al. Safety and patient perception of an insulin pen with simple memory function for children and adolescents with type 1 diabetes - The REMIND study. Pediatr Diabetes 2011;12(Suppl 15):49
42. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycaemia. Diabetes Care 2005;28:1245-9
43. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
44. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32